Prevalence and Predictors of Androgen Receptor and Programmed Death-Ligand 1 in BRCA1-associated and Sporadic Triple-Negative Breast Cancer

npj Breast Cancer - United Kingdom
doi 10.1038/npjbcancer.2016.2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2015English

Androgen Receptor-Positive, Triple-Negative Breast Cancer

Cancer
Cancer ResearchOncology
2017English

Expression of Androgen Receptor and C-Kit (CD117) in Triple Negative Breast Cancer

Immunopathology, Allergology, Infectology
2016English

BCL11A Confers Cell Invasion and Migration in Androgen Receptor‑positive Triple‑negative Breast Cancer

Oncology Letters
Cancer ResearchOncology
2020English

Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression With Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Characterization of the Interactions Between Calmodulin and Death Receptor 5 in Triple-Negative and Estrogen Receptor-Positive Breast Cancer Cells

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2016English

Modification of BRCA1-Associated Breast Cancer Risk by the Polymorphic Androgen-Receptor CAG Repeat

American Journal of Human Genetics
Genetics
1999English

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

Clinical Cancer Research
Cancer ResearchOncology
2012English

Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy